The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
1578483 |
36 |
Rationally designed"dipeptoid" analogues of CCK. A Free-Wilson/Fujita-Ban analysis of some alpha-methyltryptophan derivatives as CCK-B antagonists. |
Parke-Davis Neuroscience Research Centre |
11000005 |
16 |
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists. |
James Black Foundation |
9438020 |
67 |
Second generation"peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. |
Warner-Lambert |
7684452 |
66 |
Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and"mixed" CCK-A/CCK-B antagonists. |
Parke-Davis Neuroscience Research Centre |
1573640 |
54 |
Amide bond replacements incorporated into CCK-B selective"dipeptoids". |
Parke-Davis Neuroscience Research Center |
1635058 |
50 |
Rationally designed"dipeptoid" analogues of CCK. Acid mimics of the potent and selective non-peptide CCK-B receptor antagonist CI-988. |
Parke-Davis Neuroscience Research Centre |
1671419 |
48 |
Rationally designed"dipeptoid" analogues of CCK. alpha-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. |
Parke-Davis Research Unit |
11266174 |
51 |
Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold. |
Novartis Institute For Medical Sciences |
10866391 |
10 |
The design and synthesis of the high efficacy, non-peptide CCK1 receptor agonist PD170292. |
Ccipe-Faculte De Pharmacie |
| 66 |
Design and synthesis of a targeted set of aromatic amino acid derivatives for identification of new lead compounds |
TBA |
| 10 |
Synthesis of novel iodinated radioligands with high affinity and selectivity for CCK-B/gastrin receptors |
TBA |
| 27 |
The rational design and synthesis of non-peptide rhegnylogues of CCK-26-33 - a novel series of CCK-A selective ligands |
TBA |
| 7 |
Synthesis of a potent and selective non-peptide CCK-B/gastrin receptor antagonist tritiated ligand. |
TBA |
| 10 |
Cholecystokinin analogues: The ergopeptine alkaloids as models of the active conformation of CCK |
TBA |
| 22 |
Design and synthesis of novel nonpeptide CCK-B receptor antagonists |
TBA |
| 38 |
SAR study of the indole moiety of CI-988, a potent and selective CCK-B antagonist |
TBA |
| 45 |
Synthesis and pharmacological evaluation of highly potent dual histamine H2 and gastrin receptor antagonists |
TBA |
| 87 |
Design, synthesis, and pharmacological evaluation of dual histamine H2 and gastrin receptor antagonists |
TBA |
| 40 |
Novel cholecystokinin receptor ligands: Oxopiperazines derived from Boc-CCK-4 |
TBA |
| 13 |
Alternative strategies towards the identification of chemical lead compounds by rational design |
TBA |
| 23 |
Methionine replacements in biologically active peptides |
TBA |
| 12 |
α-β-didehydrotryptophan as a surrogate for α-methyltryptophan in CCK ‘peptoids’ related to CI-988. |
TBA |
| 24 |
Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class |
TBA |
| 24 |
Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry |
TBA |
| 11 |
Diastereoselective synthesis of cyclopropyl phenylalanines and their incorporation into dipeptides |
TBA |
| 34 |
Synthesis and sar study of novel CCK-B antagonists |
TBA |
| 8 |
The use of a proline ring as a conformational restraint in CCK-B receptor “dipeptoids”. |
TBA |
| 14 |
The synthesis and CCK receptor affinities of selected carboyxlic acid mimics of CI-988 - a potent and selective CCK-B antagonist |
TBA |
18614364 |
109 |
Discovery of imidazole carboxamides as potent and selective CCK1R agonists. |
Merck Research Laboratories |
9990454 |
26 |
Highly constrained dipeptoid analogues containing a type II' beta-turn mimic as novel and selective CCK-A receptor ligands. |
Instituto De QuíMica MéDica (Csic) |
9544204 |
100 |
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. |
Parke-Davis Pharmaceutical Research |
8411002 |
67 |
Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties. |
University of Paris |
16250638 |
46 |
Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists. |
James Black Foundation |
11000006 |
28 |
2,7-Dioxo-2,3,4,5,6,7-hexahydro-1H-benzo[h][1,4]diazonine as a new template for the design of CCK(2) receptor antagonists. |
James Black Foundation |
8627604 |
38 |
Non-peptide cholecystokinin-B/gastrin receptor antagonists based on bicyclic, heteroaromatic skeletons. |
James Black Foundation |
7473557 |
65 |
Improving the affinity and selectivity of a nonpeptide series of cholecystokinin-B/gastrin receptor antagonists based on the dibenzobicyclo[2.2.2]octane skeleton. |
James Black Foundation |
7966125 |
26 |
A new class of non-peptidic cholecystokinin-B/gastrin receptor antagonists based on dibenzobicyclo[2.2.2]octane. |
James Black Foundation |
2016728 |
43 |
Quinazolinone cholecystokinin-B receptor ligands. |
Eli Lilly |
1635055 |
7 |
Synthesis and X-ray crystallographic analysis of quinazolinone cholecystokinin/gastrin receptor ligands. |
Eli Lilly |